Savi Ramurthy, Ph.D., is an experienced medicinal chemist and accomplished leader with more than 20 years of drug discovery and development experience in a wide variety of therapeutic areas. She has a passion for shaping the direction of drug discovery research to deliver the best compound possible in the hopes of making a difference in patients’ lives. Savi joins HiberCell from the Novartis Institutes for BioMedical Research (NIBR) where she contributed to the discovery of multiple pre-clinical and clinical candidates and has worked on several programs in various target classes including metabolic diseases, oncology, and immuno-oncology. One of her most notable accomplishments is the delivery of clinical candidate LXH254, a selective B/CRAF inhibitor to treat cancers driven by BRAF, K, and NRAS mutations.
Savi has held leadership roles in groups aimed to foster diversity and inclusion including Women in Chemistry and Diversity and Inclusion. She has authored more than 50 publications and patents. Savi earned her Ph.D. in organic chemistry from the University of Illinois and conducted postdoctoral research at the University of Notre Dame.